Abstract
To our knowledge, the economic burden of activated PI3K delta syndrome (APDS) is not well characterized. We designed a cost model to estimate the annual direct medical costs associated with APDS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
